Last reviewed · How we verify
No Patch Control
At a glance
| Generic name | No Patch Control |
|---|---|
| Also known as | Negative Control |
| Sponsor | McNeil AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- Predictive Validity and Clinical Utility of an Ultrasound-based Quantitative Risk Score for Pressure Injury in Critically Ill Patients: A Two-Phase Sequential Study (NA)
- An AI-Based Erythema Measurement System for Psoriasis Lesions
- Traction vs. No Traction in Colonic ESD (NA)
- Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain (NA)
- The Effectiveness of Silver Alginate (Algidex) Patch in the Prevention of Central Line Infections in Very Low Birth Weight Infants (NA)
- Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer (NA)
- Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No Patch Control CI brief — competitive landscape report
- No Patch Control updates RSS · CI watch RSS
- McNeil AB portfolio CI